David L. Greenwood is the CEO of Geron Corporation, a company focused on developing therapies for cancer and other serious diseases. He has a solid educational background with a B.A. from Pacific Lutheran University and an MBA from Harvard Business...
David L. Greenwood is the CEO of Geron Corporation, a company focused on developing therapies for cancer and other serious diseases. He has a solid educational background with a B.A. from Pacific Lutheran University and an MBA from Harvard Business School. Greenwood joined Geron in 1995 and has played various roles, including Chief Financial Officer and President. He brings over 20 years of financial expertise from his previous work at J.P. Morgan. In 2011, he took on the responsibilities of President and Interim CEO, which marked a new era for Geron as it transitioned into mid-stage clinical development of its therapies. Under his leadership, the compensation model aims to align management's performance with shareholders' interests, ensuring that rewards are linked to corporate and individual performance. Interestingly, in 2011, he received total compensation of over $3 million, which included a substantial bonus for achieving company goals and the vesting of stock awards. Greenwood has also actively participated on boards of other companies, showing his commitment to the sector. His holdings in Geron Corporation include over 212,000 shares, which reflects his belief in the company's future and his stake in its success.